Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Hölig K, Schmidt H, Hütter G, Kramer M, Teipel R, Heidrich K, Zimmer K, Heidenreich F, Blechschmidt M, Torosian T, Ordemann R, Kroschinsky F, Rücker-Braun E, Gopsca L, Wagner-Drouet EM, Oelschlaegel U, Schmidt AH, Bornhäuser M, Ehninger G, Schetelig J. Hölig K, et al. Among authors: ordemann r. Bone Marrow Transplant. 2021 Mar;56(3):635-645. doi: 10.1038/s41409-020-01053-4. Epub 2020 Oct 7. Bone Marrow Transplant. 2021. PMID: 33028987 Free PMC article. Clinical Trial.
Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R, Oelschlägel U, Wetzko K, Schmiedgen M, Kramer M, Rücker-Braun E, Hölig K, von Bonin M, Heidrich K, Fuchs A, Ordemann R, Kroschinsky F, Bornhäuser M, Hütter G, Schmidt H, Ehninger G, Schetelig J, Heidenreich F. Teipel R, et al. Among authors: ordemann r. Biol Blood Marrow Transplant. 2018 Nov;24(11):2171-2177. doi: 10.1016/j.bbmt.2018.06.023. Epub 2018 Jun 21. Biol Blood Marrow Transplant. 2018. PMID: 29935214 Free article.
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Hölig K, Schmidt H, Hütter G, Kramer M, Teipel R, Heidrich K, Zimmer K, Heidenreich F, Blechschmidt M, Torosian T, Ordemann R, Kroschinsky F, Rücker-Braun E, Gopsca L, Wagner-Drouet EM, Oelschlaegel U, Schmidt AH, Bornhäuser M, Ehninger G, Schetelig J. Hölig K, et al. Among authors: ordemann r. Bone Marrow Transplant. 2022 Jan;57(1):143. doi: 10.1038/s41409-021-01523-3. Bone Marrow Transplant. 2022. PMID: 34773089 Free PMC article. No abstract available.
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
Jing D, Oelschlaegel U, Ordemann R, Hölig K, Ehninger G, Reichmann H, Ziemssen T, Bornhäuser M. Jing D, et al. Among authors: ordemann r. Bone Marrow Transplant. 2010 Oct;45(10):1489-96. doi: 10.1038/bmt.2009.381. Epub 2010 Jan 25. Bone Marrow Transplant. 2010. PMID: 20098455 Clinical Trial.
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G. Kroschinsky F, et al. Among authors: ordemann r. Transfusion. 2006 Aug;46(8):1417-23. doi: 10.1111/j.1537-2995.2006.00911.x. Transfusion. 2006. PMID: 16934080 Clinical Trial.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: ordemann r. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
57 results